All In Biotech

Drug Trial Radar · NCT07262268

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Jan 15, 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

Conditions

  • Familial Erythromelalgia

Interventions

  • BHV-7000Drug

    Participants will take blinded investigational product (IP) orally once daily

  • PlaceboDrug

    Matching placebo taken orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean of the daily average maximum pain intensity scores collected every 2 hours.Time frame: The last 3 weeks of each 4-week crossover treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site-001

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.